
Volitionrx Limited (VNRX) Stock Forecast & Price Target
Volitionrx Limited (VNRX) Analyst Ratings
Bulls say
VolitionRX Ltd is poised for topline growth driven by potential upfront and milestone payments, along with future recurring royalties. The company is expanding its customer base for the Nu.Q Discover services through a strategic co-marketing agreement, enhancing its market reach. Additionally, the recent research license and exclusive commercial option rights agreement with the Immunoassay Technology Center of Werfen indicates a strong partnership that could further bolster Volition’s position in the diagnostics market.
Bears say
VolitionRX Ltd faces significant risks that may negatively impact its financial stability and future performance, including the potential for failures in the clinical development of its diagnostic products. Additionally, the company could struggle to secure necessary license agreements and may fail to gain market traction, which would further hinder revenue growth. Furthermore, concerns regarding dilution and going concern issues, including the risk of delisting, create added uncertainties surrounding the company's financial outlook.
This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.
Volitionrx Limited (VNRX) Analyst Forecast & Price Prediction
Start investing in Volitionrx Limited (VNRX)
Order type
Buy in
Order amount
Est. shares
0 shares